What is Cosmo Pharmaceuticals NV Revenue per Share?
Cosmo Pharmaceuticals NV's revenue per share for the
six
months ended in Jun. 2023 was CHF2.64.
Cosmo Pharmaceuticals NV's revenue per share for the trailing twelve months (TTM) ended in Jun. 2023 was CHF6.30.
During the past 12 months, the average Revenue Per Share Growth Rate of Cosmo Pharmaceuticals NV was 38.80% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 9.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 0.20% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Cosmo Pharmaceuticals NV's Revenue per Share or its related term are showing as below:
CHIX:COPNz'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -28.2 Med: -1.75 Max: 32
Current: 9.6
During the past 13 years, Cosmo Pharmaceuticals NV's highest 3-Year average Revenue Per Share Growth Rate was 32.00% per year. The lowest was -28.20% per year. And the median was -1.75% per year.
CHIX:COPNz's 3-Year Revenue Growth Rate is ranked better than 58.18% of 923
companies
in the Drug Manufacturers industry
Industry Median: 6.5
vs CHIX:COPNz: 9.60
Cosmo Pharmaceuticals NV Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cosmo Pharmaceuticals NV's Revenue per Share
For the Drug Manufacturers - General subindustry, Cosmo Pharmaceuticals NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Pharmaceuticals NV's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo Pharmaceuticals NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cosmo Pharmaceuticals NV's PS Ratio falls into.
Cosmo Pharmaceuticals NV Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Cosmo Pharmaceuticals NV's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF6.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Pharmaceuticals NV (CHIX:COPNz) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Cosmo Pharmaceuticals NV Revenue per Share Related Terms
Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Cosmo Pharmaceuticals NV (CHIX:COPNZ) Business Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHIX:COPNZ has been successfully added to your 